Can Keppra (levetiracetam) cause dizziness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Keppra Cause Dizziness?

Yes, Keppra (levetiracetam) can cause dizziness, which is one of the most commonly reported adverse effects of this medication, occurring in approximately 9% of adult patients taking the drug compared to 4% on placebo. 1

Frequency and Clinical Significance

  • Dizziness occurs in 9% of adult patients with partial onset seizures treated with levetiracetam versus 4% of placebo-treated patients, making it one of the four most common adverse effects alongside somnolence, asthenia, and infection 1

  • In pediatric patients (ages 4-16 years), dizziness occurs in 7% of levetiracetam-treated patients compared to 2% on placebo 1

  • The dizziness is typically mild to moderate in intensity and most commonly occurs during the first 4 weeks of treatment 1

Additional Context from Clinical Studies

  • A systematic review of 3,347 patients exposed to levetiracetam found that dizziness was among the predominant adverse effects, occurring most frequently during the first month of treatment 2

  • In dose-response studies, dizziness was reported in patients receiving doses ranging from 1000-4000 mg/day, though the frequency increased with higher doses 3, 4

  • The adverse effect profile shows that dizziness occurs alongside other central nervous system effects such as somnolence and asthenia, suggesting a shared mechanism related to CNS depression 5

Practical Implications

  • Patients should be advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to determine whether it adversely affects their performance 1

  • The dizziness typically does not require drug discontinuation in most patients, as discontinuation rates due to adverse events were only 6.9-10.9% for all levetiracetam doses combined (including all adverse effects, not just dizziness) 5

  • No dose adjustment is specifically recommended for dizziness alone, though clinicians should monitor patients during the initial treatment period when this adverse effect is most likely to occur 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.